Second generation mTOR inhibitors Action point of first and second generation mTOR inhibitors on PI3K/AKT/mTOR pathwayThe second generation of mTOR inhibitors is known as ATP-competitive mTOR kinase inhibitors. mTORC1/mTORC2 dual inhibitors  are designed to compete with ATP in the catalytic site of mTOR. They inhibit all of the kinase-dependent functions of mTORC1 and mTORC2 and therefore, block the feedback activation of PI3K/AKT signaling, unlike rapalogs that only target mTORC1. These types of inhibitors have been developed and several of them are being tested in clinical trials . Like rapalogs, they decrease protein translation, attenuate cell cycle progression, and inhibit angiogenesis in many cancer cell lines and also in human cancer. In fact, they have been proven to be more potent than rapalogs.
Second generation mTOR inhibitors Action point of first and second generation mTOR inhibitors on PI3K/AKT/mTOR pathwayThe second generation of mTOR inhibitors is known as ATP-competitive mTOR kinase inhibitors. mTORC1/mTORC2 dual inhibitors such as torin-1, torin-2 and vistusertib, are designed to compete with ATP in the catalytic site of mTOR. They inhibit all of the kinase-dependent functions of mTORC1 and mTORC2 and block the feedback activation of PI3K/AKT signaling, unlike rapalogs , which only target mTORC1. Development of these drugs has reached clinical trials, although some, such as vistusertib, have been discontinued . Like rapalogs, they decrease protein translation, attenuate cell cycle progression, and inhibit angiogenesis in many cancer cell lines and also in human cancer. In fact, they have been proven to be more potent than rapalogs.
A
such as torin-1, torin-2 and vistusertib,
D
therefore,
R
that
, which
R
These types of inhibitors have been developed and several of them are being tested in clinical trials
Development of these drugs has reached clinical trials, although some, such as vistusertib, have been discontinued